Trial Profile

Observation of Treatment Patterns With Lucentis and Real Life Ophthalmic Monitoring, Including Optional OCT in Approved Indications

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 03 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ranibizumab (Primary)
Indications Branch retinal vein occlusion; Choroidal neovascularisation; Degenerative myopia; Diabetic macular oedema; Retinal oedema; Wet age-related macular degeneration
Focus Therapeutic Use
Acronyms OCEAN
Sponsors Novartis

Most Recent Events

01 Dec 2018 Results published in the Diabetes Therapy
28 Feb 2017 Status changed from active, no longer recruiting to completed.
27 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com